Skip to Content

Additional Content In This Section

PARADISE-MI

Objective

Status Enrolling

Condition Acute Myocardial Infarction and Congestive Heart Failure

Description

A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an AMI

Purpose

The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HFs. 

Phase III

Key Inclusion Criteria

Male or female patients ≥ 18 years of age.

2.Diagnosis of spontaneous AMI based on the universal MI definition* with   randomization to occur between 12 hours and 7 days after index event   presentation.

3.Evidence of LV systolic dysfunction and/or pulmonary congestion requiring   intravenous treatment associated with the index MI event defined as:

 ◦LVEF ≤40% after index MI presentation and prior to randomization and/or

 ◦Pulmonary congestion requiring intravenous treatment during the index

  hospitalization 

4.At least one of the following 8 risk factors:

  ◦Age ≥ 70 years

 ◦eGFR <60 mL/min/1.73 m2 based on MDRD formula at screening visit

 ◦Type I or II diabetes mellitus

 ◦Documented history of prior MI

 ◦Atrial fibrillation as noted by ECG, associated with index MI

 ◦LVEF <30% associated with index MI

 ◦Worst Killip class III or IV associated with index MI requiring intravenous treatment

◦STEMI without reperfusion therapy within the first 24 hours after

  presentation

Key Exclusion Criteria

Known history of chronic HF prior to randomization

2.Cardiogenic shock within the last 24 hours prior to randomization

3.Persistent clinical HF at the time of randomization

4.Coronary artery bypass graft (CABG) performed or planned for index MI

5.Clinically significant right ventricular MI as index MI

6.Symptomatic hypotension at screening or randomization

7.Patients with a known history of angioedema

8.Stroke or transient ischemic attack within one month prior to randomization

9.Known or suspected bilateral renal artery stenosis

10.Clinically significant obstructive cardiomyopathy

11.Open-heart surgery performed within one month prior to randomization or planned cardiac surgery w/in the 3 months prior to randomization

12.eGFR < 30 ml/min/1.73 m2 as measured by MDRD at screening

13.Serum potassium > 5.2 mmol /L at screening

14.Known hepatic impairment (as evidenced by total bilirubin > 3.0 mg/dL or increased ammonia levels, if performed), or history of cirrhosis with evidence of portal hypertension such as varices

15.Previous use of LCZ696 or EntrestoTM

16.History of malignancy of any organ system (other than localized basal cell carcinoma of the skin) within the past 3 years with a life expectancy of less than 1year.

17.History of hypersensitivity to the study drugs or drugs of similar chemical classes or known intolerance or contraindications to study drugs or drugs of similar chemical classes including ACE inhibitors, ARB or NEP inhibitors

18.Pregnant or nursing women or women of child-bearing potential unless they are using highly effective methods of contraception

ClinicalTrials.gov Identifier

NCT0292427

Protocol Number

CLCZ696G2301

Principal Investigator(s)
Jason Go, MD

Clinical Trial Categories

  • Cardiology
Sponsor(s)
Novartis
Contact
Dianne Vold, LPN CCRC at 701-780-1559
or dvold@altru.org